share_log

Compugen | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Feb 15 20:02
Summary by Futu AI
On February 15, 2024, Compugen Ltd., a clinical-stage cancer immunotherapy company, announced the appointment of Michelle Mahler, M.D., as its new Chief Medical Officer, effective March 1, 2024. Dr. Mahler, who joined Compugen in October 2023 as Vice President of Clinical Development, will be taking over from Henry Adewoye, M.D., who is departing the company to pursue other opportunities. Dr. Mahler brings extensive experience from her previous roles at various biotech and pharmaceutical companies, including 1 E therapeutics Ltd. and Aummune Therapeutics Ltd. She has been instrumental in preparing for the COM503 Phase 1 study in partnership with Gilead Sciences and has played a key role in ongoing triple combination studies. Compugen's CEO, Anat Cohen-Dayag, Ph.D., expressed gratitude to Dr. Adewoye for his contributions to the company's transition into a clinical stage and for advancing its clinical and regulatory strategy. Compugen is known for its computational target discovery and is developing a range of cancer immunotherapies, including COM701 and COM902, and has a partnered program, rilvegostomig, in Phase 3 development with AstraZeneca.
On February 15, 2024, Compugen Ltd., a clinical-stage cancer immunotherapy company, announced the appointment of Michelle Mahler, M.D., as its new Chief Medical Officer, effective March 1, 2024. Dr. Mahler, who joined Compugen in October 2023 as Vice President of Clinical Development, will be taking over from Henry Adewoye, M.D., who is departing the company to pursue other opportunities. Dr. Mahler brings extensive experience from her previous roles at various biotech and pharmaceutical companies, including 1 E therapeutics Ltd. and Aummune Therapeutics Ltd. She has been instrumental in preparing for the COM503 Phase 1 study in partnership with Gilead Sciences and has played a key role in ongoing triple combination studies. Compugen's CEO, Anat Cohen-Dayag, Ph.D., expressed gratitude to Dr. Adewoye for his contributions to the company's transition into a clinical stage and for advancing its clinical and regulatory strategy. Compugen is known for its computational target discovery and is developing a range of cancer immunotherapies, including COM701 and COM902, and has a partnered program, rilvegostomig, in Phase 3 development with AstraZeneca.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.